SCOTTISH biotechnology company TC BioPharm (TCB) has secured a £500,000 regional selective assistance (RSA) grant to help it develop a treatment for different types of cancer.
The funding will support a strategic collaboration announced by TCB yesterday with MEDINET, a Tokyo-listed immuno-cell therapy company.
Under the deal, MEDINET will licence its innovative cell therapy to TCB exclusively for its clinical development in the UK and Europe.
The technology involves using patients' own immune cells grown in culture to target cancer, and is said to have safely treated patients in Japan.
Under the guidance of professor Jeff Evans, of the University of Glasgow, TCB hopes to treat the first patients in early 2015, working with established cancer clinics in Glasgow and Southampton.
The RSA grant, awarded through Scottish Enterprise (SE), will support the creation of 35 jobs over the next three years. TCB is also working with SE on business planning, investment strategy and international opportunities through Scottish Development International.
It was also announced yesterday that TCB has signed a 10-year lease on a 5000 sq ft site at Eurocentral's Maxim Office Park as its new Scottish base.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereComments are closed on this article